Front Page News
Call-to-Action: Senate Health Care Bill Released and Vote Expected Next Week
Yesterday, members of the Senate released draft text of their much awaited legislation called the Better Care Reconciliation Act (“Better Care Act”) of 2017. As […]
Read More ›Cure SMA Update – Senate Healthcare Bill
The US Senate is currently working on legislation to modify the Affordable Care Act. Though details of the Senate’s plan are not yet available, legislation […]
Read More ›Launch of Phase 2 SMA Industry Collaboration Announced
Cure SMA is pleased to announce the launch of Phase 2 of our SMA Industry Collaboration. The SMA Industry Collaboration is a multi-faceted partnership that […]
Read More ›2017 Annual SMA Conference Booklet Now Posted
The 2017 Annual SMA Conference Booklet is now posted. The booklet includes: A complete schedule with information about the special events we’ve got planned including: […]
Read More ›SMA Newborn Screening Moves Forward in Missouri and Florida
The spinal muscular atrophy community is celebrating significant progress toward adding SMA to newborn screening panels in two states. Missouri to Become the First State […]
Read More ›AveXis Announces Alignment with the FDA on Company’s GMP Commercial Manufacturing Process for AVXS-101
AveXis today announced alignment with the U.S. Food and Drug Administration (FDA) on the company’s Good Manufacturing Practice (GMP) commercial manufacturing process for AVXS-101 following […]
Read More ›Cure SMA Advocacy Activities for the 2017 Year-to-Date
The first half of 2017 has been an active six months for Cure SMA and SMA advocates. Cure SMA and members of our community have […]
Read More ›Update: President’s Budget Proposes Significant Cuts to Federal Health Programs That Are Critically Important to SMA Patients and Families
The President recently released his detailed budget proposal for Fiscal Year 2018, which proposed significant funding cuts to numerous federal programs, including many that have […]
Read More ›Anthem Updates Insurance Policy for Spinraza
Anthem Inc. recently announced an updated insurance policy for the use of Spinraza (nusinersen) for treatment of spinal muscular atrophy. The revised policy expands criteria […]
Read More ›European Commission Grants Marketing Authorization for Spinraza, Making it First Approved SMA Treatment in the European Union
Biogen announced today that the European Commission (EC) has granted a marketing authorization for Spinraza for the treatment of spinal muscular atrophy (SMA), making it […]
Read More ›